SGLT2 Inhibitors – The New HF Therapies on the Block
Published: 25 August 2020
-
Views:
377
-
Likes:
7
-
Views:
377
-
Likes:
7
-
Up Next
-
2m 46sPart 1 Welcome & Introductions Subodh Verma
-
20m 55sPart 2 A Brief History of SGLT2 Inhibitors Subodh Verma
-
12m 55sPart 3 What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective Nikolaus Marx
-
9m 55sPart 4 How Might Future Trials Affect How I Treat My Patients? Shelley Zieroth
Overview
In this Educational Symposium from the e-SPACE Heart Failure Global Web-Conference, Subodh Verma, Nikolaus Marx and Shelley Zieroth discuss SGLT2 inhibitors covering their history, a clinical perspective into what we have learned about them and how future trials might affect clinical practice.
Learning objectives
- Raise Awareness of SGLT2 Inhibitors as Cardiovascular Therapies With Cardio–Renal Benefits
- Highlight Appropriate Patients for Initiation of an SGLT2 Inhibitor and Share With Cardiologists the Well-Established Safety Profile and Clinical Considerations for SGLT2 Inhibitor Treatment
- Inform Cardiologists of the Current Evidence and Ongoing Trials for SGLT2 Inhibitors in Patients With HF
Agenda
- 5 mins - Welcome & introduction - Subodh Verma
- 15 mins - A brief history of SGLT2 inhibitors - Subodh Verma
- 15 mins - What have we learned about SGLT2 inhibitors? A clinical perspective - Nikolaus Marx
- 15 mins - How might future trials affect how I might treat my patients? - Shelley Zieroth
- 10 mins - Faculty discussion (pre-recorded) - All Faculty
- Close - Subodh Verma
- Live Q&A and discussion - All Faculty
More from this programme
Part 1
Welcome & Introductions
| 1 session | |
| Welcome & Introductions | Watch now |
Part 2
A Brief History of SGLT2 Inhibitors
| 1 session | |
| A Brief History of SGLT2 Inhibitors | Watch now |
Part 3
What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective
Part 4
How Might Future Trials Affect How I Treat My Patients?
Part 5
Panel discussion
| 1 session | |
| Panel discussion | Watch now |
Faculty Biographies
Subodh Verma
Dr Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery.
Dr Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in seven ongoing global heart failure trials.
Nikolaus Marx
Professor of Medicine
Prof Nikolaus Marx is a Professor of Medicine / Cardiology at RWTH University Hospital Aachen, Aachen, DE.
Prof Marx's interests include cardiovascular disease in patients with comorbidities including diabetes and chronic kidney disease.
Shelley Zieroth
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.